Supernus Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Supernus Pharmaceuticals, Inc.

Kahn Swick & Foti is investigating the proposed acquisition of Supernus Pharmaceuticals by Indivior, under which Supernus shareholders would receive 1.5401 Indivior common shares per Supernus share. The investigation will assess whether the exchange terms and sale process are adequate for Supernus shareholders, creating potential transaction-related legal uncertainty.

Analysis

This is low-signal, event-driven noise rather than evidence of a transaction-threatening legal development. Plaintiff-firm investigations following announced mergers typically produce supplemental disclosures and immaterial fee settlements; absent a filed injunction motion, a revised exchange ratio, or a disclosed board-process defect, they should not alter expected closing probability over the next 1-3 months.

The relevant exposure is the fixed exchange ratio: SUPN holders are synthetically long INDV between signing and close, so any widening in the SUPN/INDV ratio discount can reflect closing-risk repricing, INDV-specific fundamental risk, or borrow/friction rather than litigation. A genuine legal catalyst would be a demand for appraisal-like remedies, an amended proxy with new valuation inputs, or regulator-driven delay—not the initiation of an investigation itself.

Strategically, the acquirer is likely seeking CNS-scale diversification, but the market should focus on whether expected commercial synergies offset integration complexity and INDV's legacy concentration and policy sensitivity. Over 6-18 months, failure to deliver revenue synergy or unexpected erosion in the acquired neurology/psychiatry franchise would pressure the combined-company multiple even if the transaction closes cleanly. The contrarian view is that any litigation-driven SUPN weakness without a corresponding change in deal timing creates a mechanical arbitrage entry, not a fundamental short signal.

Key Decisions for Investors

• Do not trade the legal headline directionally. Set an event-driven alert for a filed injunction, amended proxy, revised exchange ratio, shareholder-vote delay, or regulatory second request; those developments, rather than law-firm publicity, would justify reassessing close probability.
• Monitor the SUPN price divided by INDV price against the 1.5401 share entitlement daily. If the implied spread widens materially versus its post-announcement range without a new regulatory or financing development, evaluate long SUPN / short 1.5401 INDV shares as a market-neutral merger-arbitrage position, sized to borrow availability and closing-date uncertainty.
• For existing SUPN exposure, hedge INDV beta rather than treating SUPN as a standalone CNS equity until closing. The principal near-term risk is a decline in INDV equity value, which mechanically reduces the value of the consideration even if closing probability is unchanged.
• Avoid shorting SUPN solely on litigation risk. A bearish position becomes more defensible only if new disclosures indicate a credible process challenge, the merger spread remains persistently wide after proxy filing, or INDV guidance/earnings materially weakens and raises renegotiation risk.